Literature DB >> 11142688

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.

M M Malingré1, J H Schellens, O van Tellingen, H Rosing, F J Koopman, K Duchin, W W Huinink, M Swart, J H Beijnen.   

Abstract

The objective of this study was to compare the quantitative excretion of paclitaxel and metabolites after i.v. and oral drug administration. Four patients received 300 mg/m2 paclitaxel orally 30 min after 15 mg/kg oral cyclosporin A, co-administered to enhance the uptake of paclitaxel. Three weeks later these and three other patients received 175 mg/m2 paclitaxel by i.v. infusion. Blood samples, urine and feces were collected up to 48-96 h after administration, and analyzed for paclitaxel and metabolites. The area under the plasma concentration-time curve of paclitaxel after i.v. administration (175 mg/m2) was 16.2 +/- 1.7 microM x h and after oral administration (300 mg/m2) 3.8 +/- 1.5 microM x h. Following i.v. infusion of paclitaxel, total fecal excretion was 56 +/- 25%, with the metabolite 6alpha-hydroxypaclitaxel being the main excretory product (37 +/- 18%). After oral administration of paclitaxel, total fecal excretion was 76 +/- 21%, of which paclitaxel accounted for 61 +/- 14%. In conclusion, after i.v. administration of paclitaxel, excretion occurs mainly in the feces with the metabolites as the major excretory products. Orally administered paclitaxel is also mainly excreted in feces but with the parent drug in highest amounts. We assume that this high amount of parent drug is due to incomplete absorption of orally administered paclitaxel from the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11142688     DOI: 10.1097/00001813-200011000-00004

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

Review 1.  Oral delivery of taxanes.

Authors:  M M Malingré; J H Beijnen; J H Schellens
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 2.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

Authors:  Frederik E Stuurman; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

4.  Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

Authors:  Milly E de Jonge; Alwin Dr Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

5.  A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.

Authors:  S A Veltkamp; B Thijssen; J S Garrigue; G Lambert; F Lallemand; F Binlich; A D R Huitema; B Nuijen; A Nol; J H Beijnen; J H M Schellens
Journal:  Br J Cancer       Date:  2006-08-22       Impact factor: 7.640

6.  The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.

Authors:  M M Malingré; J H Schellens; O Van Tellingen; M Ouwehand; H A Bardelmeijer; H Rosing; F J Koopman; M E Schot; W W Ten Bokkel Huinink; J H Beijnen
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

7.  Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies.

Authors:  Shahrooz Saremi; Rassoul Dinarvand; Abbas Kebriaeezadeh; Seyed Nasser Ostad; Fatemeh Atyabi
Journal:  Biomed Res Int       Date:  2013-07-21       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.